Novo Nordisk and its competitor Eli Lilly are expected to make more than $100 billion in revenue from their GLP-1 drugs, including new oral weight-loss medications
It belongs to the family of GLP-1 receptor agonists (GLP-1-RA), initially used for the treatment of people with obesity-associated type 2 diabetes and later for people with obesity without diabetes, commercialised for use in obesity under the name Wegovy
Am J Physiol Endocrinol Metab 283:E1173E1177 Wynne K, Park AJ, Small CJ et al (2005) Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial
35 Furthermore, even in patients who achieve weight loss, only 50% to 60% demonstrate a decrease in the incidence of diabetes
The Lancet Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials Qingyang Shi et al.
Early signs include dark urine, dizziness, dry mouth, and reduced urinationall requiring immediate hydration intervention and provider contact
